Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 3INTERVENTIONAL

Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer

The Use of Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Who Are Treated With Radioactive Iodine for Thyroid Cancer

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Radio-iodine therapy for thyroid cancer 2. Radioiodine therapy ≥150 mCi 3. Age 18 or older Who Should NOT Join This Trial: 1. Use of eye drops, other than artificial tears 2. History of periocular trauma with tear duct involvement/lacrimal gland trauma 3. History of lacrimal drainage disease: canaliculitis, dacryocystitis 4. Prior radiotherapy 5. Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel) 6. Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia) 7. Nasolacrimal duct obstruction at baseline Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Radio-iodine therapy for thyroid cancer 2. Radioiodine therapy ≥150 mCi 3. Age 18 or older Exclusion Criteria: 1. Use of eye drops, other than artificial tears 2. History of periocular trauma with tear duct involvement/lacrimal gland trauma 3. History of lacrimal drainage disease: canaliculitis, dacryocystitis 4. Prior radiotherapy 5. Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel) 6. Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia) 7. Nasolacrimal duct obstruction at baseline

Treatments Being Tested

DRUG

Artificial Tears Methylcellulose

Participants will self-administer the artificial tears according to the schedule.

Locations (1)

Vanderbilt University Medical Center
Nashville, Tennessee, United States